Healthy
Conditions
Brief summary
The objective was to investigate the effect of different doses of BI 10773 on the bioavailability of pioglitazone after multiple oral doses of both drugs
Interventions
DRUGPioglitazone
DRUGPioglitazone - low dose
DRUGBI 10773 - low dose
DRUGBI 10773 - medium dose
DRUGBI 10773 - high dose
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male subjects according to the following criteria: medical history, physical examination, vital signs ((blood pressure (BP), pulse rate (PR), 12-lead electrocardiogram (ECG)), clinical laboratory tests 2. Age 18 to 55 years (incl.) 3. BMI 18.5 to 29.9 kg/m2 (incl.) 4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practise (GCP) and the local legislation
Exclusion criteria
1. Any finding of the medical examination including blood pressure (BP), pulse rate (PR) and electrocardiogram (ECG) deviating from normal and of clinical relevance 2. Any evidence of a clinically relevant concomitant disease 3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 4. Surgery of the gastrointestinal tract (except appendectomy) 5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 6. History of relevant orthostatic hypotension, fainting spells or blackouts. 7. Chronic or relevant acute infections 8. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) 9. Intake of drugs with a long half-life (more than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial 10. Participation in another trial with an investigational drug within two months prior to administration or during the trial 11. Smoker (more than 10 cigarettes or more than 3 cigars or more than 3 pipes/day) 12. Inability to refrain from smoking on trial days 13. Alcohol abuse (more than 30 g/day) 14. Drug abuse 15. Blood donation (more than 100 mL within four weeks prior to administration or during the trial) 16. Excessive physical activities (within one week prior to administration or during the trial) 17. Alanine aminotransferase (ALT) outside the normal range or any other laboratory value outside the reference range that is of clinical relevance 18. Inability to comply with dietary regimen of trial site 19. Galactose or lactose intolerance, galactose or glucose malabsorption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) | Before each dosing, up to 10 days |
| Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) | Before each dosing, up to 10 days |
Secondary
| Measure | Time frame |
|---|---|
| AUCτ,1 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration within the first dosing interval) | Before each dosing, up to 10 days |
| AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) | Before each dosing, up to 10 days |
| C24,N (concentration of the analyte in plasma at 24 h after administration of the Nth dose) | Before each dosing, up to 10 days |
| λz (terminal elimination rate constant of the analyte in plasma) | Before each dosing, up to 10 days |
| t½ (terminal half-life of the analyte in plasma) | Before each dosing, up to 10 days |
| tmax (time from last dosing to maximum measured concentration of the analyte in plasma) | Before each dosing, up to 10 days |
| MRTpo (mean residence time of the analyte in the body at steady state after oral administration) | Before each dosing, up to 10 days |
| CL/F (apparent clearance of the analyte in the plasma after extravascular administration) | Before each dosing, up to 10 days |
| Vz/F (apparent volume of distribution during the terminal phase λz following extravascular administration) | Before each dosing, up to 10 days |
| Metabolite to parent ratio | Before each dosing, up to 10 days |
| fet1-t2 (fraction of dose excreted unchanged in urine over the time interval t1 to t2) | Day1 (-1-0, 0-4, 4-8, 8-12, and 12-24 h), Day 7 (143-144, 144-148, 148-152, 152-156, and 156-168 h) |
| CLR (renal clearance of the analyte in plasma afer extravascular administration) | Day1 (-1-0, 0-4, 4-8, 8-12, and 12-24 h), Day 7 (143-144, 144-148, 148-152, 152-156, and 156-168 h) |
| Cmax (maximum concentration of the analyte in plasma) | Before each dosing, up to 10 days |
| Number of patients with abnormal findings in physical examination | up to 30 days after drug administration |
| Number of patients with abnormal changes in laboratory parameters | up to 30 days after drug administration |
| Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG) | up to 30 days after drug administration |
| Number of patients with clinically significant changes in vital signs | up to 30 days after drug administration |
| Assessment of tolerability by investigator on a 4-point scale | up to 10 days |
| Number of patients with adverse events | up to 51 days |
| Aet1-t2 (amount of analyte eliminated in urine over the time interval t1 to t2 ) | Day1 (-1-0, 0-4, 4-8, 8-12, and 12-24 h), Day 7 (143-144, 144-148, 148-152, 152-156, and 156-168 h) |
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration) | Before each dosing, up to 10 days |
Outcome results
None listed